Cell Line: U-937

Cell Description: human lymphoma, histiocytic; macrophage

Culture Medium: RPMI 1640 medium with 4.5 g/L glucose, sodium bicarbonate, 2mM L-glutamine, 1,0 mM sodium pyruvate + 10% fetal bovine serum (optional with 10 mM HEPES)

Subculturing: Cultures can be maintained by addition or replacement of fresh medium. Establish new cultures at 0.1 to 1 X 10⁵ viable cells/ml, and maintain between 5 x 10⁵ and 1 X 10⁶ cells/ml.

Fluid Renewal: add fresh medium every 3 to 4 days

Morphology: monocyte

Growth Properties: suspension

Sterility: Tests for Mycoplasma, bacteria and fungi were negative

Biosafety Level: 1

Receptors Expressed: immunoglobulin (Fc); complement (C3)

Products: lysozyme; beta-2-microglobulin (beta 2 microglobulin); tumor necrosis factor (TNF), also known as tumor necrosis factor alpha (TNF-alpha, TNF alpha), after stimulation with phorbol myristic acid (PMA)

Depositor: Koren

Comments: established from a 37-year-old caucasian male

ECACC number: 87010802

ATCC designation: CRL-1593.2

References:

Sundstrom C and Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int. J. Cancer 17: 565-577, 1976. Ralph P et al. Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J. Exp. Med. 143: 1528-1533, 1976. Andersson, L.C.; Galmberg, C.G.; Ekblom, P., Gene expression during normal and malignant differentiation. London: Academic Press; 1985:pp. 57-72 . Rosenfeld, C.; Serrou, B., eds., International symposium on new trends in human immunology and cancer immunotherapy. Paris: Doin Editeurs; 1980:pp. 271-292. Koren HS et al. In vitro activation of a human macrophage-like cell line. Nature 279: 328-331, 1979. Gidlund M et al. Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848-850, 1981. Olsson I et al. Induction of differentiation of the human histiocytic lymphoma cell line U-937 by 1 alpha,25-dihydroxycholecalciferol. Cancer Res. 43: 5862-5867, 1983. Morimoto H et al. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 53: 2591-2596, 1993. Giovannangeli C et al.

Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus

as a target. Proc. Natl. Acad. Sci. USA 94: 79-84, 1997. Brigino E et al. Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA 94: 3178-3182, 1997.